Further studies are needed to reveal the underlying AZD9668 ic50 mechanisms. MORI DAISUKE1, INOUE KAZUNORI1, HAMANO TAKAYUKI2, MATSUI ISAO1, SHIMOMURA AKIHIRO1, KUSUNOKI YASUO1, NAKANO CHIKAKO1, OBI YOSHITSUGU1, TSUBAKIHARA YOSHIHARU2, ISAKA YOSHITAKA1, RAKUGI HIROMI1 1Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine; 2Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine Introduction: Left ventricular
hypertrophy (LVH) and a resultant heart failure are the leading causes of death in patients with chronic kidney disease (CKD). Therefore, it is important to establish novel strategies to prevent LVH in CKD. Studies on vitamin D receptor knockout mice have revealed that active vitamin D may be one of the promising agents that ameliorate LVH. Therefore, in the current study, we examined preventive Regorafenib price effects of maxacalcitol (22-oxacalcitriol (OCT)), a clinically used less calcemic analogue of active vitamin D, on LVH in hemi-nephrectomized rats. Methods: Six-week-old male Wister rats were subjected to heminephrectomy and then divided into four groups; normal saline + vehicle (N+V), normal saline + OCT (N+O), angiotensin II (Ang II) + vehicle (A+V), and Ang II + OCT (A+O). Vehicle or OCT at a dose of 0.15 μg/kg BW was administered subcutaneously twice a day. We also
examined the effects of OCT on hypertrophy using cultured neonatal rat ventricular 3-mercaptopyruvate sulfurtransferase myocytes (NRVM). Results: In comparison with groups N+V and N+O, group A+V had increased heart weight, cross sectional area of cardiomyocytes, and LVH-associated genes. Because it is well established that an activation of calcineurin A
(CnA)-NFAT pathway in cardiomyocyte causes pathological LVH, we examined the status of this pathway in these rats. In comparison with groups N+V and N+O, group A+V had higher activity of CnA. Elevated expression of moderately calcineurin interacting protein 1 (MCIP-1), a down-stream component of CnA-NFAT pathway, in group A+V also confirmed the activation of CnA-NFAT pathway in group A+V. All of these changes were suppressed in group A+O in a blood-pressure-independent manner. To understand the underlying mechanism more precisely how OCT suppressed LVH, we performed in vitro examinations using NRVM. An overexpression of constitutive-active form CnA in the NRVM induced MCIP-1 expression and hypertrophy. OCT suppressed these changes in a dose dependent manner. Conclusion: Our findings may provide a novel approach for the suppression of pathological LVH in CKD. HAN SEUNG SEOK1, PARK JAE YOON1, KIM MYOUNGHEE2, JOO KWON WOOK1, KIM YON SU1, KIM DONG KI1 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; 2Department of Dental Hygiene, College of Health Science, Eulji University, Gyeonggi-do, Korea Introduction: The elderly constitutes a substantial proportion of patients suffering from the end-stage renal disease.